209 results
Page 2 of 11
8-K
EX-99.1
ab2ba4z0t
9 Nov 22
Jazz Pharmaceuticals Announces Third Quarter 2022 Financial Results and Raises Total Revenue Guidance Mid-point
4:07pm
8-K
EX-99.1
i19r5
19 Oct 22
Jazz Pharmaceuticals and Zymeworks Announce Exclusive License Agreement to Develop and Commercialize Zanidatamab, a HER2-Targeted Bispecific Antibody
6:59am
8-K
EX-99.1
nzxoj8bio8zpcz0i
3 Aug 22
Jazz Pharmaceuticals Announces Second Quarter 2022 Financial Results and Affirms 2022 Financial Guidance
4:07pm
DEFA14A
u8us z5pnwyja19
7 Jul 22
Additional proxy soliciting materials
4:18pm
8-K
EX-99.1
rud9nq06u60rjldg6
4 May 22
Jazz Pharmaceuticals and Sumitomo Pharma Announce Exclusive License Agreement to Develop and Commercialize DSP-0187, a Potent, Highly Selective Oral Orexin-2 Receptor Agonist
4:17pm
8-K
EX-99.1
94ywm9 go8
4 May 22
Jazz Pharmaceuticals Announces First Quarter 2022
4:13pm
8-K
EX-99.1
flv7qu9w17jerr
28 Mar 22
Jazz Pharmaceuticals Announces Agreement to Divest Sunosi® (solriamfetol) to Axsome Therapeutics
8:55am
8-K
EX-99.1
yk2fejh pqa9z
1 Mar 22
Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2021
4:07pm
8-K
EX-99.1
h80u7jo
10 Jan 22
Announces $5 billion revenue target for 2025
7:47am
8-K
EX-99.1
mcdvob
9 Nov 21
Jazz Pharmaceuticals Announces Third Quarter 2021
4:07pm